BTAI
(NASDAQ)
25.21
+2.87  (+11.38%)
Volume (24h): 415.61K Day Range: 21.00 - 25.94
Market Cap: 508.80M 52W Range: 3.76 - 43.63
Mar-24-20 08:23PM Biotech stocks have held up better than the broader market — and these five are potential winnersMarketWatch
02:46PM Biotech stocks have held up better than the broader market — and these five are potential winnersMarketWatch
Mar-19-20 11:15AM BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY TrialsGlobeNewswire
Mar-17-20 02:55PM BTAI: On Track for Multiple Data Readouts in 2020…Zacks Small Cap Research
Mar-09-20 11:00AM BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateGlobeNewswire
10:00AM BioXcel Therapeutics, Inc. to Host Earnings CallACCESSWIRE
Mar-02-20 12:00PM BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and WebcastGlobeNewswire
Feb-28-20 01:20PM BTAI: Financing Strengthens Balance Sheet; Raising Valuation to $92/Share…Zacks Small Cap Research
Feb-26-20 12:00PM BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor ConferencesGlobeNewswire
Feb-20-20 12:30PM BioXcel Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire
Feb-19-20 09:54PM BioXcel Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
12:21PM The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLABenzinga
Feb-18-20 12:00PM BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501GlobeNewswire
Feb-07-20 12:00PM BioXcel Therapeutics to Present at the 2020 BIO CEO & Investor ConferenceGlobeNewswire
Feb-06-20 12:47PM The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOsBenzinga
Feb-05-20 12:00PM BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal SymptomsGlobeNewswire
Jan-28-20 11:13PM Get In on the AI Health Care Revolution With Globus, BioXcel, Apple, Amazon and GoogleGuruFocus.com
Jan-25-20 02:28PM We're Keeping An Eye On BioXcel Therapeutics's (NASDAQ:BTAI) Cash Burn RateSimply Wall St.
Jan-10-20 11:45AM BTAI: Potentially Transformative Year Ahead for BioXcel…Zacks Small Cap Research
Jan-07-20 12:00PM BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with DementiaGlobeNewswire
Dec-30-19 12:00PM BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar DisorderGlobeNewswire
Dec-23-19 12:42AM Hedge Funds Have Never Been This Bullish On BioXcel Therapeutics, Inc. (BTAI)Insider Monkey
Dec-11-19 12:00PM BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor TypesGlobeNewswire
Dec-06-19 11:40AM BTAI: Pivotal Phase 3 Trials for BXCL501 to Initiate by End of 2019…Zacks Small Cap Research
Dec-03-19 12:00PM BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDAGlobeNewswire
Nov-26-19 12:00PM BioXcel Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare ConferenceBusiness Wire
Nov-21-19 11:30AM BTAI: Phase 3 Trials of BXCL501 in Agitation to Initiate Before Year End…Zacks Small Cap Research
Nov-14-19 12:00PM BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business UpdateBusiness Wire
Nov-07-19 12:00PM BioXcel Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and WebcastBusiness Wire
Oct-30-19 10:00AM BTAI: Initiating Coverage of BioXcel Therapeutics, Inc.; AI Driven Drug DevelopmentZacks Small Cap Research
Oct-27-19 01:51PM How Many BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Did Insiders Buy, In The Last Year?Simply Wall St.
Oct-24-19 12:00PM BioXcel Therapeutics to Present at the 26th Annual Prostate Cancer Foundation Scientific RetreatBusiness Wire
Oct-10-19 12:00PM BioXcel Therapeutics Highlights Upcoming Major MilestonesGlobeNewswire
Sep-26-19 01:11PM BioXcel Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire
Sep-25-19 08:27PM BioXcel Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
Sep-18-19 12:00PM BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital DevicesGlobeNewswire
Sep-04-19 12:00PM BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)GlobeNewswire
Aug-20-19 12:00PM BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501GlobeNewswire
Aug-06-19 11:30AM BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business UpdateGlobeNewswire
Jul-31-19 12:00PM BioXcel Therapeutics to Present at the Canaccord Genuity 2019 Annual Growth ConferenceGlobeNewswire
Jul-30-19 08:01PM BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business UpdateGlobeNewswire
Jul-29-19 06:34PM Is BioXcel Therapeutics (NASDAQ:BTAI) A Risky Investment?Simply Wall St.
Jul-26-19 04:21PM BioXcel's CEO On BXCL501: 'This Is A Pretty Unique Drug'Benzinga
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. It has clinical partnership with Nektar Therapeutics. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)